KRAS and non-small cell lung carcinoma: Nearly half of the KRAS-mutant tumors harbor concomitant TP53 mutations, followed by LKB1 (18% to 28%) and KEAP1 (24%), while less than 5% of KRAS-mutant NSCLC patients have another oncogenic-driven co-mutation, such as BRAF, EGFR, PIK3CA, or MET amplification, with no concurrent ALK or ROS1 rearrangements described [27,28,29,36,37,38].